Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30026962HIVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS30026963HIVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS20001445HPVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS20001070HPVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS20041095HPVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS20038300HPVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS20046168HPVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS20044845HPVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS20042956HPVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS20065709HPVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TCGA Plot Options
Drug Information
GeneCHRM3
DrugBank IDDB09185
Drug NameViloxazine
Target IDBE0000045
UniProt IDP20309
Regulation Typeantagonist
PubMed IDs34003459; 32943948
CitationsFindling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH: Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021 Jun;35(6):643-653. doi: 10.1007/s40263-021-00825-w. Epub 2021 May 18.@@Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V: New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. doi: 10.2147/JEP.S256586. eCollection 2020.
GroupsApproved; Investigational; Withdrawn
Direct ClassificationPhenol ethers
SMILESCCOC1=CC=CC=C1OCC1CNCCO1
Pathways
PharmGKB
ChEMBLCHEMBL306700